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Temporary interruption of treatment in three patients is not a high 
rate of pauses that may affect the outcome of cancer treatment (local 
control of the disease). It also shows the small negative effect of 
these treatments during application and good clinical acceptance in 
groups of elderly patients. Definitive interruption of treatment 
occurred in only 2 patients. They were not as a result of acute toxicity 
produced during radiotherpay, which reaffirms the option of external 
radiation therapy as a treatment in elderly based on toxicity criteria 
and/or fragility of the patient.Hypofractionation may be a valid 
treatment regimen in elderly patients with comorbidities. 
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Purpose/Objective: To compare orthovoltage X-ray therapy (OXRT) 
and standard treatment for reducing pain in knee OA.  
Materials and Methods: Twentyone patients having Grade 1 of knee 
joints OA evaluated by Kellgren Lawrence Score, were prospectively 
randomized to OXRT (n=11) or standard treatment consisting of 
combined Chondroitin (CS) and Glucosamine Sulfates (GS) medicine 
'Theraflex' and non-steroid anti-inflammatory drug Ketoprofen (n=10). 
Dose prescription for OXRT (XStrahl-200, Gulmay Medical Inc., USA) 
was 4,8 Gy in 10 fractions for 3.5 weeks. Theraflex was given 1 dose, 
containing CS 400 mg and GS 500 mg 3 times per day during 3 weeks in 
combination with Ketoprofen 100 mg 3 times a day. Supportive 
treatment consisting of Theraflex twice daily and Ketoprofen 100 mg 
up to 2 times a day begun from the fourth week during 3 months. The 
pain severity was evaluated by visual-analogue scale (VAS). The 
comparative analysis, considering the values in VAS being continuous, 
was performed using Mann-Whitney test. 
Results: Median age of patients in OXRT group was 53.2 (SD, 2.80) and 
Theraflex group 55.1 (SD,3.2). The proportions of males were 45.5% 
and 40.0% for OXRT and Theraflex groups respectively. The 
distribution on initial characteristics was equal. Initially, the pain 
severity in OXRT group was 7.3 (95% CI, 6.6-7.9) and 7.5 (95% CI, 6.8-
8.3) for the patients of Theraflex group. After 3 months of follow-up 
the pain level by VAS has been reduced by 4,3 (Q1 3.0 - Q3 5.6) and 
2,4(Q1 0.6 - Q3 3.3), ?=0.006, U=17.00 among patients of OXRT and 
Theraflex groups, respectively. 
Conclusions: Orthovoltage X-ray therapy allows decreasing 
significantly pain after 3 month. The evolution of cartilage thickness 
and long-term safety should be measured further.  
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Purpose/Objective: To assess the efficacy and safety of neoadjuvant 
chemoradiotherapy in elderly patients with resectable oesophageal 
carcinoma by a systematic review. 
Materials and Methods: Medline, Embase, ISI Web of Knowledge, 
Cochrane Library and China Biological Medicine Database were 
systematically searched in September 2012. Studies comparing the 
outcomes of neoadjuvant chemoradiotherapy or surgery only for 
elderly patients with oesophageal carcinoma were included without 
language restriction. The minimum threshold age used to define the 
elderly was 60 years. The primary outcomes were long-term survival, 
postoperative mortality and complication. All statistical analyses were 
undertaken in Review Manager 5.1 and random effect model was used. 
Results: Out of the initially 144 hits, four studies of 1221 patients (1 
randomized controlled trial, 3 cohort studies) were included. Meta-
analyses based on 3 studies suggested that neoadjuvant 
chemoradiotherapy was not associated with significant improvement 
in disease-free survival (HR=1.08, 95%CI: 0.91-1.28; p=0.38) and 
overall survival (HR=1.12, 95%CI: 0.94-1.33; p=0.19) than surgery 
alone in elderly patients. The 3 years survival rate was 40% vs. 34% in 
neoadjuvant group and surgery alone group, while 5 years survival 
rate was 18% vs. 20%, respectively. No significant survival difference 
was found (p>0.05). And there was also no significantly difference in 
postoperative mortality and major complications (including 
respiratory diseases, cardiovascular diseases, renal failure, and 
anastomotic leak) based on 3 studies. Quality of life was reported in 
one study which showed no significant difference  between two groups 
except for less hospital discharge in neoadjuvant group. 
Conclusions: Comparing with surgery alone, neoadjuvant 
chemoradiotherapy didn't show significantly survival benefit in the 
elderly with oesophageal carcinoma. Though studies were few in 
number, the current available evidence prompted that the elderly 
may get less benefit from neoadjuvant chemoradiotherapy than 
younger. The effect of neoadjuvant chemoradiotherapy for the elderly 
esophageal cancer is still unproven, more clinical studies are needed 
for the definite results.If possible, additional subgroup analysis by 
different ages in randomized controlled trials may help. 
   
 ELECTRONIC POSTER: CLINICAL TRACK: PALLIATION/ 
SUPPORTIVE CARE/PATIENT SUPPORT  
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Purpose/Objective: For several decades, radiotherapy (RT) has been 
widely used to treat metastatic spinal tumors. This study was designed 
to assess the feasibility and early clinical outcome of high dose RT to 
treat such tumors, using helical tomotherapy (HT). 
Materials and Methods: Between June 2009 and December 2011, 51 
sites in 36 patients were treated with high dose RT using HT for spinal 
metastasis. Treatment outcomes and dosimetric analyses of spinal 
cord were retrospectively evaluated.  
Results: Median follow-up was 11.5 months (range, 6–34.6) for 
surviving patients. The median fractional dose and the number of 
fractions in the primary HT arm were 2,700 cGy and 3 fractions, 
respectively. Actuarial 6-month local control rates was 85.7%, and 
symptomatic vertebral compression fractures developed in five 
patients after median 4.2 months. Among 13 patients with 19 
metastatic sites who showed pre-treatment impairment in neurologic 
function, five patients (with seven sites) in whom symptoms were mild 
showed improvement in neuronal function. The median pre-treatment 
VAS score of 7 decreased to a median of 3 after HT (P < 0.001) at 
median 1 month (range, 0.5-3.2). No significant morbidity developed 
during follow-up except for one grade 3 esophagitis.  
Conclusions: The use of HT to treat metastatic spinal tumors appears 
to be both safe and reliable in terms of local tumor control and early 
pain relief. Local progression and the risk of compression fracture in 
patients with pre-existing spinal instability remain as the principal 
factors of limiting improved clinical and functional outcomes. Optimal 
dose fractionation schemes and appropriate patient selections are 
required to achieve better outcomes with high dose RT using HT. 
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Purpose/Objective: Most malignant lymphomas are effectively 
treated by chemotherapy, but some of them relapse and become 
refractory. Treatment of relapsed chemoresistant or refractory 
lymphoma is difficult in many cases and salvage chemotherapy with or 
without autologous stem cell transplant is not always effective. Best 
supportive care is often chosen for such patients; however, palliative 
radiotherapy (RT) is thought to be very useful for some cases. The aim 
of this study was to analyze the treatment outcomes of patients who 
received palliative RT for relapsed or refractory malignant lymphoma. 
Materials and Methods: From 2008-2012, 160 patients with malignant 
lymphoma were treated at the Department of Radiation Oncology in 
our institute. Among them, 20 patients (12.5%) were referred with 
palliative intent, consisting of 17 aggressive lymphomas (13 diffuse 
large B-cell lymphomas and 4 other lymphomas) and 3 indolent 
lymphomas. Six patients had a bulky tumor and 10 patients showed 
multiple masses. The treatment outcomes of palliative RT were 
retrospectively analyzed. 
Results: The median age at the time of RT was 60 years old (range: 
42-92), and 13 patients (65%) were male. Three patients died during 
treatment. The median follow-up from RT was 3 months(range: 0.75-
19). Overall response rate was 94% (complete response: 36%, partial 
response: 58%). The median overall survival was 3 months (range: 
0.75-19). In RT for 48 sites of 20 patients, median dose of treatment 
was 34 Gy (range: 4-50). Nineteen patients (95%) showed a significant 
response to RT (pain relief, prevention of neurological symptoms, 
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etc.), and they had significant improvements in their quality of life. 
The other patient showed neither clinical nor image changes. 
Conclusions: Palliative RT was effective for patients with relapsed or 
refractory malignant lymphoma. Improved quality of life is expected 
for such patients regardless of their limited life expectancy. 
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Purpose/Objective: Most evaluations of toxicity are based on 
international toxicity scores. We wanted to retrospectively evaluate 
other clinical parameters such as hospitalization days, use of opioid 
drugs, infectious comorbility, chemotherapy dose intensity and RT 
interruptions. 
Materials and Methods: Between September 2004 and June 2010, 64 
pts underwent CT-RT for oropharynx cancer stage III-IV. Mean age was 
63 years (48-75 y) but only 4 pts. were older than 70 years. Forty-four 
pts (68,8%) underwent definitive concomitant CT-RT, 10 pts (15,6%) 
underwent definitive sequential CT-RT, 10 pts (15,6%) underwent 
postoperative adjuvant concomitant CT-RT. The concomitant 
treatments were DPP based for 47 pts (87%) (DDP every three weeks, 
DDP weekly and DDP-5FU in 82,9%, 12,8% and 4,3% respectively) and 7 
pts received Cetuximab only. The sequential CT-RT was TPF for 7 pts. 
and DDP-5FU for 3 pts.. Of patients undergoing definitive CT-RT, 21 
pts (38,9%) were treated with IMRT with simultaneous integrated 
boost to doses of 54-66 Gy in 30 fractions, 14 pts (25,9%) were treated 
with a simple 3D 3-field technique to a dose of 70 Gy in 35 fractions 
and 19 pts (35,2%) were treated with an elaborate 3D conformal 5-7-
field technique to a dose of 70 Gy in 35 fractions. Post-operative 
radiotherapy was performed with 3-field 3D-RT to a dose of 63 Gy in 
35 fractions. 
Results: Sixty-one pts (95,3%) received the planned radiotherapy, 5 
pts (7,8%) needed a radiotherapy break for treatment toxicity (less 
than 1 week) while 3 pts had a definitive interruption of the RT: 2 pts. 
for a tumor progression and 1 pts. for toxicity at 66 Gy of planned 70 
Gy. Results regarding dose intensity of chemotherapy were as follows: 
 
 Median  
cycles 
Mean cycles 
DDP every 3 weeks 3 (3) 2.6 
DDP(weekly) 4 (7) 4.3 
Cetuximab 6 (7) 5.7 
 
Fourteen pts. (21,5%) were hospitalized from the beginning of 
treatment on patient request and 20 pts (31,2%) were hospitalized 
during the treatment for deteriorating physical condition. Nineteen 
pts (29,6%) needed nutritional support (parenteral or enteral 
nutrition) and the duration of the supplementary nutrition was more 
than 9 weeks for 9 pts (47,3%). Fifteen pts (23,4%) needed opioid 
therapy and 19 pts (29,6%) needed codeine-based medication. 
Thirteen pts. (20,3%) developed a clinical infection with 9 of them 
presenting with pneumonia. No treatment related deaths occured. 
Toxicity for patients treated with IMRT was lower than for patients 
treated with 3D-RT for all analyzed endpoints. These data are, 
however, clearly biased because when IMRT was clinically established 
at the department, predominantly young patients with few 
comorbidities were chosen for IMRT  
Conclusions: This analysis provides a different view on acute toxicity 
of RT-CT for head and neck cancer, providing comprehensive 
objective data in a large patient cohort. Though the reported toxicity 
is substantial, almost all treatments could be completed as intended. 
This emphasizes the importance of appropriate patient selection and 
intensified supportive care. Analysis of late toxicity and clinical 
results for this patient cohort is under way.  
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Purpose/Objective: Cancer patients and their families frequently 
report that coordination of support services is disjointed and subject 
to regional variation in New Zealand. They are often confused about 
who to turn to for care after completion of specialist oncology 
treatment. It is during this period that issues such as medium to long 
term side effects of the cancer and its treatments and the need for 
social and psychological support often become apparent. A recent 
report compiled for the National Office of the Cancer Society of New 
Zealand indicates that lack of clarity about the role of GPs in ongoing 
care contributes significantly to thisissue. Both GPs and oncologists 
differ in their expectations of the follow up support that GPs should 
provide for patients and their family after completion of specialist 
care. This presentation will discuss the GP perspective on the issue. 
Materials and Methods: Three semi-structured individual interviews 
and seven focus groups of five to nine participants were conducted in 
the lower North Island and lower South Island of NZ. Participants were 
GPs servicing a mixture of urban, rural and varying socio-economic 
demographics. Interviews and focus groups were audio recorded and 
later transcribed. Coding was performed using NVivo9. Data analysis 
follows a constructivist approach to grounded theory. Peer coding and 
analysis was used. 
Results: Core themes that emerged included: variable standards of 
communication between GPs and oncologists;a belief that GPs have a 
significant role to play in the supportive care of patients; comparison 
with a range of chronic conditions for models to guide the role of GPs 
in the care for cancer patients; concerns over currency of their 
oncology knowledge; frustration with barriers to patients accessing GP 
services; limited awareness of services and information which may be 
of benefit to patients and discussion around cultural considerations 
pertinent to the NZ setting. 
Conclusions: GPs want to actively engage in supporting patients 
manage their cancer in the short and long term. GPs share a growing 
perception of cancer as a chronic condition needing a structured 
approach to ongoing management. They perceive that this is best 
achieved through partnerships with oncologists, other health 
professionals and patients themselves. The next phase of the research 
aims to establish the perceptions of oncologists to complete the 
picture and construct viable pathways to improving the overall service 
to patients. 
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Purpose/Objective: Induced oral mucositis (IOM) is still a common 
and severe acute side-effect of many oncologic treatments, especially 
in patients treated for head and neck cancer. It may affect quality of 
life, require supportive care and impact treatment planning and its 
efficacy. Low-level laser therapy (LLLT) seems to promote pain relief 
and reduces IOM incidence and severity. It has been recommended for 
these patients as a treatment option but without any consensus in the 
LLLT procedure. New recommendations and perspectives for clinical 
trials will be discussed. 
Materials and Methods: Step by step, the efficacy of soft laser in the 
management of induced oral mucositis has been evaluated during the 
last two decades. Its effectiveness and level of recommendation got 
stronger with time. We will report and discuss some major results and 
the latest recommendations published on this topic. 
Results: The major clinical results have been reported and analysed 
last year in a first meta-analysis. Eleven randomized placebo-
controlled trials were selected with a total of 415 patients treated 
with chemotherapy or radiotherapy for head and neck cancer. The 
relative risk for developing IOM was significantly reduced after LLLT 
but only for a dose between 1 to 6 Joules per point. Pain, severity and 
duration of IOM grade ≥ 2 were also reduced without difference with 
placebo for possible side-effects. Nine years after the positive results 
published for patients treated by radiotherapy alone, a new 
randomized, multicentric, phase III trial for patients treated with new 
standard treatment, using LLLT in accordance to recent 
recommendations is ongoing. Seven centers are actually opened for 
this trial which should include a hundred patients. 
Conclusions: The very encouraging results of LLLT in the prevention 
and treatment of IOM in patients treated by chemotherapy or 
radiotherapy for advanced head and neck cancer could soon be 
proposed as a new standard of care, according to the Multinational 
Association of Supportive Care in Cancer (MASCC) criteria. Modern 
lasers are less time consuming and extraoral applicators for a possible 
use by trained paramedical staff could be helpful to complete 
clinician practice. A preventive dose of 2 J/cm2 and a curative dose of 
4 J/cm2 if using a red wavelength lasers are now recommended.  
   
 
